EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

209P Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer

D. Orbach, R-H. Xu, C. Qi, C.M. Zwaan, R.S. McDermott, A. Italiano, M. Tahara, M. Casanova, D-I. Burcoveanu, K. Guiver, N. Neu, C. Mussi und 4 weitere

ESMO Rare Cancers · 2026-03 · 5 · 100415

DOI: 10.1016/j.esmorc.2026.100415 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ESMO Rare Cancers, 2026-03. Verfasst von D. Orbach und 15 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Pharmaceuticals Bayer.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Förderung

  • Pharmaceuticals Bayer

Zitieren

APA

Orbach, D., Xu, R., Qi, C., Zwaan, C., McDermott, R., Italiano, A., Tahara, M., Casanova, M., Burcoveanu, D., Guiver, K., Neu, N., Mussi, C., Cuesta, E. D. L., Laetsch, T., Drilon, A., & Hong, D. (2026). 209P Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. ESMO Rare Cancers, 5, 100415. https://doi.org/10.1016/j.esmorc.2026.100415

Vancouver

Orbach D, Xu R, Qi C, Zwaan C, McDermott R, Italiano A, et al. 209P Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer. ESMO Rare Cancers. 2026;5:100415. doi:10.1016/j.esmorc.2026.100415

BibTeX
@article{Orbach2026,
  author = {Orbach, D. and Xu, R-H. and Qi, C. and Zwaan, C.M. and McDermott, R.S. and Italiano, A. and Tahara, M. and Casanova, M. and Burcoveanu, D-I. and Guiver, K. and Neu, N. and Mussi, C. and Cuesta, E. De La and Laetsch, T. and Drilon, A. and Hong, D.},
  title = {209P Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer},
  journal = {ESMO Rare Cancers},
  year = {2026},
  volume = {5},
  pages = {100415},
  doi = {10.1016/j.esmorc.2026.100415}
}
Kostenlos starten →